nach oben

Erschienen in:

06.10.2020 | Review articles

Effects of SARS-CoV-2 and its functional receptor ACE2 on the cardiovascular system

verfasst von: Mingzhe Li, Siyang Chen, Xiaochen Xiang, Qiang Wang, Xiaoliu Liu

Erschienen in: Herz | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

The clinical manifestations of COVID-19 are mainly respiratory symptoms, but some patients present with cardiovascular system disease such as palpitations and shortness of breath as the first or secondary symptoms. In this paper, we describe the characteristics of SARS-CoV‑2 and its functional receptor angiotensin-converting enzyme 2 (ACE2). Furthermore, we explore the impact of virus-induced myocardial damage, decreased ACE2 activity, immune imbalance, hypoxemia, and heart damage caused by antiviral drugs.

Wong ACP et al (2019) Global epidemiology of bat coronaviruses. Viruses 11(2):174–196PubMedCentral

Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273PubMedPubMedCentral

Velavan TP, Meyer CG (2020) The COVID-19 epidemic. Trop Med Int Health 25(3):278–280PubMedPubMedCentral

Perlman S, Netland J (2009) Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 7(6):439–450PubMedPubMedCentral

Turner AJ et al (2004) ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 25(6):291–294PubMedPubMedCentral

Wang H et al (2008) SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway. Cell Res 18(2):290–301PubMed

Wan Y et al (2020) Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. https://doi.org/10.1128/JVI.00127-20CrossRef

Wrapp D et al (2020) Cryo-EMstruc-tureofthe2019-nCoV spike in the prefusion conformation. Science 367(6483):1260–1263PubMedPubMedCentral

Zhang H et al (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV‑2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 3:1–5

10.

Souza Santos RA et al (2018) The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev 98(1):505–553

11.

Miller AJ, Arnold AC (2019) The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications. Clin Auton Res 29(2):231–243PubMed

12.

Oliveira Andrade JM et al (2017) The angiotensin converting enzyme 2 (ACE2), gut microbiota, and cardiovascular health. Protein Pept Lett 24(9):827–832PubMed

13.

Wang D et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069PubMed

14.

Alhogbani T (2016) Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann Saudi Med 36(1):78–80PubMedPubMedCentral

15.

Grant PR et al (2003) Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med 349(25):2468–2469PubMed

16.

Zhao J et al (2003) Clinicopathology and pathogenesis of severe acute respiratory syndrome. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 17(3):217–223PubMed

17.

Khan S et al (2020) The emergence of a novel coronavirus (SARS-coV-2), their biology and therapeutic options. J Clin Microbiol 3:187–120

18.

Oudit GY et al (2009) SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 39(7):618–625PubMedPubMedCentral

19.

Simões E Silva AC, Martins Teixeira M (2016) ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. Pharmacol Res 107:154–162

20.

Mendoza-Torres E et al (2015) ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis 9(4):217–237PubMed

21.

Liu Y et al (2020) Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung in jury. Sci China Life Sci 63(3):364–374PubMedPubMedCentral

22.

Sun ML et al (2020) Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 43(3):219–222PubMed

23.

Walsh KB et al (2011) Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A 108(29):12018–12023PubMedPubMedCentral

24.

Wong CK et al (2004) Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136(1):95–103PubMedPubMedCentral

25.

Huang C et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506PubMed

26.

Xu Z et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 18:S2213–2600

27.

Jiang F et al (2020) Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 35(5):1545–1549

28.

Deng SQ, Peng HJ (2020) Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 9(2):575–675PubMedCentral

29.

Prabhakar NR et al (2005) Cardiovascular alterations by chronic intermittent hypoxia: importance of carotid body chemoreflexes. Clin Exp Pharmacol Physiol 32(5–6):447–449PubMed

30.

Foster GE et al (2010) Intermittent hypoxia increases arterial blood pressure in humans through a renin-angiotensin system-dependent mechanism. Hypertension 56:369–377PubMed

31.

Troncoso Brindeiro CM et al (2007) Reactive oxygen species contribute to sleep apnea-induced hypertension in rats. Am J Physiol Heart Circ Physiol 293:H2971–H2976PubMed

32.

Ryan S et al (2006) Predictors of elevated nuclear factor-B-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 174:824–830PubMed

33.

Saito M et al (2003) Relations of plasma high-sensitivity C‑reactive protein to traditional cardiovascular risk factors. Atherosclerosis 167(1):73–79PubMed

34.

Wolf D, Ley K (2019) Immunity and inflammation in atherosclerosis. Circ Res 124(2):315–327PubMedPubMedCentral

35.

Beaudin AE et al (2017) Impact of obstructive sleep apnoea and intermittent hypoxia on cardiovascular and cerebrovascular regulation. Exp Physiol 102(7):743–763PubMed

36.

Park SY et al (2019) Post-exposure prophylaxis for middle east respiratory syndrome in Healthcare workers. J Hosp Infect 101(1):42–46PubMed

37.

DeCarolis DD et al (2017) Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin: twelve-week post-treatment follow-up. Ann Pharmacother 51(5):439–440PubMed

38.

Hashemian SM et al (2020) A review on remdesivir: a possible promising agent for the treatment of COVID-19. Drug Des Devel Ther 14:3215–3222PubMedPubMedCentral

39.

Mulangu S et al (2019) A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med 381:2293–2303PubMed

40.

Gao J et al (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14(1):72–73PubMed

41.

Zhong Q et al (2009) Antiviral activity of arbidol against coxsackie virus B5 in vitro and in vivo. Arch Virol 154(4):601–607PubMedPubMedCentral

42.

Liu Y et al (2020) Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 63:364–374PubMedPubMedCentral

Titel: Effects of SARS-CoV-2 and its functional receptor ACE2 on the cardiovascular system
verfasst von: Mingzhe Li
Siyang Chen
Xiaochen Xiang
Qiang Wang
Xiaoliu Liu
Publikationsdatum: 06.10.2020
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 7/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-020-04989-x

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Prevention and treatment of venous thromboembolism in cancer patients

Onco-Cardiology: tackling the ugly

Echocardiography and biomarkers for the diagnosis of cardiotoxicity

ARENA – Projekt Vorhofflimmern in der Rhein-Neckar-Region